An observation that batch hydrogenation of a key atorvastatin intermediate at the Rosario Foundation pilot plant suffered from inconsistent diastereoselectivity prompted this research into whether continuous flow processing could tighten the stereochemical outcome. The intermediate in question the tert-butyl ester of the dihydroxy heptenoic acid side chain requires selective reduction of a carbon-carbon double bond without epimerizing the adjacent chiral centers. Eight continuous hydrogenation conditions were tested in a ThalesNano H-Cube Pro flow reactor using palladium on carbon (5% Pd/C) and platinum oxide (PtO₂) catalysts at hydrogen pressures of 10-40 bar and flow rates of 0.3-1.5 mL/min. The optimized condition (5% Pd/C, 20 bar H₂, 0.5 mL/min, 50 °C) achieved 98.3% conversion with 87.3% diastereomeric excess (de) of the desired (3R,5S) diastereomer, compared with 93.8% conversion and 79.6% de in the standard batch process. The continuous system also reduced palladium leaching from 4.8 ppm (batch) to 0.7 ppm, simplifying downstream purification. Catalyst cartridge lifetime exceeded 120 hours without significant activity loss. These results demonstrate that continuous catalytic hydrogenation can improve both the stereochemical quality and the process efficiency of atorvastatin intermediate synthesis at Rosario's fine chemical production scale.